Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003–2009)

Fahey, Christine E.; Milner, Rowan J.; Barabas, Karri; Lurie, D. M.; Kow, Kelvin; Parfitt, Shannon L; Lyles, Sarah E.; Clemente, M.

doi:10.2460/javma.239.2.209

Cited by 30 publications

(47 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Avoiding chemotherapy‐associated toxicity is another challenge in dogs with twice‐relapsed or refractory lymphoma due to a combination of limited drug choices, presence of advanced stage disease and chronic myelosuppression from previous protocols. In this study, the frequency and severity of haematologic toxicities were similar to those reported in primary rescue protocols (Van Vechten et al ; Rassnick et al ; Alvarez et al ; Saba et al ; Fahey et al ; Back et al ). Dogs that required a reduced dose intensity due to haematologic toxicity did not appear to have reduced response to the VBL protocol, as the PFS (28.5 days) and MST (33 days) were not statistically different than that of dogs that did not require reduction (29.5 days and 47.5 days respectively, P=0.171).…”

Section: Discussionsupporting

confidence: 86%

“…Numerous rescue protocols for dogs with relapsed or refractory lymphoma have been reported, including MOPP (mustargen, vincristine, procarbazine and prednisone) (Rassnick et al 2002 ), DMAC (dexamethasone, melphalan, actinomycin D and cyctosine arabinoside) (Alvarez et al 2006 ), MOMP (mechlorethamine, vincristine, melphalan and prednisone) (Back et al 2015 ), LOPP (lomustine, vincristine, procarbazine and prednisone) (Fahey et al 2011 ), ADIC (doxorubicin and dacarbazine) (Van Vechten et al 1990 ), single-agent DTIC (dacarbazine) (Griessmayr et al 2009 ) and CCNU (lomustine) +/− L-asparaginase (Moore et al 1999 ;Saba et al 2009 ) among many more. Secondary response rates, defined as the percentage of dogs achieving a complete or partial remission, vary from 35 to 77%.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014)

Lenz

Robat

Stein

2016

J of Small Animal Practice

View full text Add to dashboard Cite

OBJECTIVES The objective of this study was to retrospectively evaluate response and outcome of dogs with multicentric lymphoma treated with single‐agent vinblastine as a second rescue. METHODS Medical records from 39 client‐owned dogs receiving vinblastine rescue treatment (having relapsed on or following completion of UW‐Madison and CCNU/L‐asparaginase protocols), between 2005 and 2014, were reviewed for information regarding clinical presentation, diagnostic testing, drug dosage, number of treatments, side effects, response and outcome. RESULTS The median starting dose of vinblastine was 2·6 mg/m2 (1·7 to 2·8 mg/m2), administered weekly until disease progression. Of the 39 dogs treated, 3 dogs (7·7%) achieved a complete remission, 7 dogs (17·9%) achieved a partial response, 18 dogs (46·2%) maintained stable disease and 11 (28·2%) had progressive disease. Ten dogs (25·6%) developed a grade III or IV neutropenia, and 4 dogs (10·3%) developed grade III or IV thrombocytopenia (one dog in both categories). After starting vinblastine, the median progression‐free survival was 29·5 days (0 to 77 days) and overall median survival time was 46 days (4 to 250 days). Duration of first remission was identified as a positive predictor of outcome. CLINICAL SIGNIFICANCE Single‐agent vinblastine is well tolerated in dogs with relapsed or refractory lymphoma. Responses were incomplete and short‐lasting.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014)

Lenz

Robat

Stein

2016

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…Dogs presenting to Perth Veterinary Oncology (PVO) for chemotherapy in the period between February 2012 and August 2013 with an adequate neutrophil count, and automated and manual platelet counts (MPCs) of less than 200 000 µL −1 were prospectively enrolled into the study. To be included for statistical analysis, doses of chemotherapy administered to thrombocytopenic dogs were either considered to be standard doses as per the literature, or were documented to be the maximum tolerated dose for the individual based on adverse effects (excluding thrombocytopenia) at higher doses (Fig. ).…”

Section: Methodssupporting

confidence: 68%

Evaluation of the risks of chemotherapy in dogs with thrombocytopenia

Finlay¹,

Wyatt²,

Black

2015

Vet Comparative Oncology

View full text Add to dashboard Cite

Thrombocytopenia is commonly encountered in veterinary oncology. Currently, there are no standard guidelines regarding the administration of chemotherapy to the patients with thrombocytopenia. This observational epidemiological cohort study aimed to determine whether thrombocytopenic dogs were at increased risk of gastrointestinal adverse effects (vomiting, diarrhoea, inappetence) or haemorrhage following administration of standard doses of chemotherapy. The adverse effects following 77 prospectively identified episodes of thrombocytopenia (platelet count, <200 000 µL ) were compared with the adverse effects experienced in a retrospective cohort (platelet count >200 000 µL ), and evaluated by statistical analysis. Overall, there was no statistically significant difference in the incidence of gastrointestinal adverse effects or haemorrhage between thrombocytopenic and control dogs. The control group of dogs with lymphoma were statistically more likely to experience vomiting as an adverse effect of chemotherapy (P = 0.028). The results presented here showed no evidence for an increased risk of gastrointestinal adverse effects or haemorrhage in thrombocytopenic dogs after receiving standard doses of chemotherapy.

show abstract

“…Using this protocol, 76% of dogs had hematologic toxicoses (38% had neutropenia and 60% had thrombocytopenia) and 78% of dogs experienced gastrointestinal AEs. The LOPP protocol was developed as an alternative to the MOPP protocol due to the unavailability of mechlorethamine and the complicated protocol …”

Section: Discussionmentioning

confidence: 96%

Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs

Morgan

O’Connell

Thomson

et al. 2018

Vet Comparative Oncology

View full text Add to dashboard Cite

Canine T cell lymphoma has previously been found to be a poor prognostic indicator compared with its B cell counterpart. The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma. There have been several studies investigating alternative protocols for T cell lymphoma. This study investigated the use of a modified lomustine, vincristine, procarbazine and prednisolone protocol as a first line treatment in 35 dogs with T Cell lymphoma. Median progression free survival (PFS) time for all 35 dogs was 431 days with a 6-month, 1-year, 2-year, and 3-year PFS of 69%, 54%, 29%, and 12%. Median survival time (MST) was 507 days. Twenty-nine dogs attained a complete response and had a median PFS time of 509 days. Thirty dogs experienced adverse events during the protocol, with 73% of these being grade 1 or 2. This protocol has shown increased median PFS time and MST compared with previous studies and suggests its use as a first line chemotherapy protocol against canine T cell lymphoma.

show abstract

Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003–2009)

Abstract: The University of Florida LOPP protocol may be an acceptable alternative to the mechlorethamine, vincristine, procarbazine, and prednisone protocol as a rescue protocol for dogs with lymphoma.

Cited by 30 publications

References 30 publications

Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014)

Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014)

Evaluation of the risks of chemotherapy in dogs with thrombocytopenia

Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs

Contact Info

Product

Resources

About